Lewis Katharine Louise, Cheah Chan Yoon
Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.
Linear Clinical Research, Nedlands, Australia.
Leuk Lymphoma. 2024 Jun;65(6):720-735. doi: 10.1080/10428194.2024.2323085. Epub 2024 Mar 7.
Diffuse large B-cell lymphoma (DLBCL) may be cured with anti-CD20 based chemoimmunotherapy in the majority of cases, however, relapsed/refractory disease occurs in 30-40% patients, and despite significant recent therapeutic advances, continues to represent an unmet clinical need. Bispecific antibodies represent a novel class of therapy currently in development for relapsed/refractory B-cell lymphoma. This review discusses the background clinical need, mechanism of action, and clinical data including efficacy and toxicity for bispecific antibodies in DLBCL, focusing on the most advanced class in development; CD20 targeting T-cell engaging antibodies. Emerging possibilities for future use of bispecific antibodies is also discussed, including novel and cytotoxic combination regimens in relapsed and first-line settings.
弥漫性大B细胞淋巴瘤（DLBCL）在大多数情况下可通过基于抗CD20的化疗免疫疗法治愈，然而，30%-40%的患者会出现复发/难治性疾病，尽管近期治疗取得了重大进展，但这一疾病仍代表着尚未满足的临床需求。双特异性抗体是目前正在开发用于复发/难治性B细胞淋巴瘤的一类新型疗法。本综述讨论了双特异性抗体治疗DLBCL的背景临床需求、作用机制以及临床数据，包括疗效和毒性，重点关注开发中最先进的一类；靶向CD20的T细胞衔接抗体。还讨论了双特异性抗体未来使用的新可能性，包括复发和一线治疗中的新型和细胞毒性联合方案。
